Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Henrietta Abodakpi"'
Autor:
Yuen Yi Hon, Jie Wang, Henrietta Abodakpi, Anand Balakrishnan, Michael Pacanowski, Sushanta Chakder, Patroula Smpokou, Kathleen Donohue, Yow‐Ming C. Wang
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 12, Pp 2438-2457 (2023)
Abstract This paper summarizes key features of the dose‐finding strategies used in the development of 11 approved new molecular entities that are first‐in‐class enzyme replacement therapy (ERT), with a goal to gain insight into the dose explora
Externí odkaz:
https://doaj.org/article/1de7a515a1ad422dad1cb6819654c91f
Autor:
Erik Skoglund, Henrietta Abodakpi, Rafael Rios, Lorena Diaz, Elsa De La Cadena, An Q. Dinh, Javier Ardila, William R. Miller, Jose M. Munita, Cesar A. Arias, Vincent H. Tam, Truc T. Tran
Publikováno v:
Case Reports in Infectious Diseases, Vol 2019 (2019)
Externí odkaz:
https://doaj.org/article/d5324465fb114d3e927ca77a74e120c6
Autor:
Erik Skoglund, Henrietta Abodakpi, Rafael Rios, Lorena Diaz, Elsa De La Cadena, An Q. Dinh, Javier Ardila, William R. Miller, Jose M. Munita, Cesar A. Arias, Vincent H. Tam, Truc T. Tran
Publikováno v:
Case Reports in Infectious Diseases, Vol 2018 (2018)
Two pairs of ceftolozane/tazobactam susceptible/resistant P. aeruginosa were isolated from 2 patients after exposure to β-lactams. The genetic basis of ceftolozane/tazobactam resistance was evaluated, and β-lactam-resistant mechanisms were assessed
Externí odkaz:
https://doaj.org/article/47ed234790a04dd889c2fbfca540c2a7
Publikováno v:
Clinics in Laboratory Medicine. 39:473-485
As a class, β-lactamase inhibitors have proved successful in extending the clinical utility of β-lactam antibiotics by circumventing β-lactamase-mediated resistance. However, the rapid evolution of these β-lactamases calls for a critical reevalua
Autor:
Alise Gramatniece, Leonard Leibovici, Henrietta Abodakpi, Vincent H. Tam, Dafna Yahav, Christian G. Giske
Publikováno v:
Clin Microbiol Rev
The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanism
Autor:
Henrietta Abodakpi, Christian G. Giske, Alise Grāmatniece, Vincent H. Tam, Leonard Leibovici, Dafna Yahav
Publikováno v:
Clin Microbiol Rev
The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam-β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms
Autor:
Katrina Chan, Amelia K. Sofjan, Kimberly R. Ledesma, Truc T. Tran, Henrietta Abodakpi, Rachel Altman, Weiqun Wang, Michael Nikolaou, Paul R. Merlau, Vincent H. Tam
Publikováno v:
J Antimicrob Chemother
ObjectivesReduced in vitro β-lactam activity against a dense bacterial population is well recognized. It is commonly attributed to the presence of β-lactamase(s) and it is unknown whether the inoculum effect could be diminished by a β-lactamase in
Autor:
Ana María Sánchez Díaz, Henrietta Abodakpi, Vincent H. Tam, Kai-Tai Chang, Amelia K. Sofjan, Todd M. Lasco, Rafael Cantón, Katrina Chan
Publikováno v:
Journal of Chemotherapy. 30:115-119
To improve prescribing of empiric therapy, the local molecular epidemiology of extended-spectrum beta-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemases (KPCs) in bloodstream isolates of K. pneumoniae were evaluated. Isolates resistant to th
Autor:
Henrietta Abodakpi, Elsa De La Cadena, Javier Ardila, Lorena Diaz, Jose M. Munita, Erik Skoglund, Truc T. Tran, Cesar A. Arias, Rafael Rios, Vincent H. Tam, William R. Miller, An Q Dinh
Publikováno v:
Case Reports in Infectious Diseases
Case Reports in Infectious Diseases, Vol 2019 (2019)
Case Reports in Infectious Diseases, Vol 2019 (2019)
Autor:
Henrietta Abodakpi, Ana María Sánchez-Díaz, Rafael Cantón, Song Gao, Vincent H. Tam, Kai-Tai Chang
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Piperacillin-tazobactam has been proposed as an alternative to carbapenems for the treatment of infections caused by extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae However, limited understanding of optimal dosing strategies for th